Pathways and progress in improving drug delivery through the intestinal mucosa and blood-brain barriers

Therapeutic Delivery

Volumn 5, Issue 10, 2014, Pages 1143-1163

  Laksitorini, Marlyn ^a   Prasasty, Vivitri D ^a   Kiptoo, Paul K ^a   Siahaan, Teruna J ^a  

^a UNIVERSITY OF KANSAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD31 ANTIGEN; CELL SURFACE RECEPTOR; CLAUDIN; CYCLOPEPTIDE; DOXORUBICIN; LIPOSOME; MULTIDRUG RESISTANCE PROTEIN; NANOPARTICLE; OCCLUDIN; PRODRUG; PROTEIN ZO1; TEMOZOLOMIDE; UVOMORULIN; CARRIER PROTEIN; DRUG; DRUG CARRIER;

BLOOD BRAIN BARRIER; CACO 2 CELL LINE; CELL ADHESION; CELL JUNCTION; CELL MEMBRANE; CELL SURFACE; DESMOSOME; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG DIFFUSION; DRUG DISTRIBUTION; DRUG PENETRATION; DRUG TRANSPORT; HUMAN; HYDROGEN BOND; INTESTINE MUCOSA; INTESTINE MUCOSA PERMEABILITY; PROTEIN PROTEIN INTERACTION; REVIEW; TIGHT JUNCTION; ANIMAL; CHEMISTRY; DIFFUSION; DRUG DESIGN; INTESTINE ABSORPTION; MEDICINAL CHEMISTRY; METABOLISM; PERMEABILITY;

ANIMALS; BLOOD-BRAIN BARRIER; CHEMISTRY, PHARMACEUTICAL; DIFFUSION; DRUG CARRIERS; DRUG DESIGN; HUMANS; INTESTINAL ABSORPTION; INTESTINAL MUCOSA; MEMBRANE TRANSPORT PROTEINS; PERMEABILITY; PHARMACEUTICAL PREPARATIONS; RECEPTORS, CELL SURFACE;

EID: 84912574192     PISSN: 20415990     EISSN: 20416008     Source Type: Journal    
DOI: 10.4155/tde.14.67     Document Type: Review

References (173)

1. Blikslager AT, Moeser AJ, Gookin JL, Jones SL, Odle J. Restoration of barrier function in injured intestinal mucosa. Physiol. Rev. 87(2), 545-564 (2007).
2. Wolburg H, Lippoldt A. Tight junctions of the blood-brain barrier: development, composition and regulation. Vascul. Pharmacol. 38(6), 323-337 (2002).
3. Stamatovic SM, Keep RF, Andjelkovic AV. Brain endothelial cell-cell junctions: how to "open" the blood brain barrier. Curr. Neuropharmacol. 6(3), 179-192 (2008).
4. Gonzalez-Mariscal L, Betanzos A, Nava P, Jaramillo BE. Tight junction proteins. Prog. Biophys. Mol. Biol. 81(1), 1-44 (2003).
5. Schneeberger EE, Lynch RD. The tight junction: a multifunctional complex. Am. J. Physiol. Cell. Physiol. 286(6), C1213-C1228 (2004).
6. Medina R, Rahner C, Mitic LL, Anderson JM, Van Itallie CM. Occludin localization at the tight junction requires the second extracellular loop. J. Membr. Biol. 178(3), 235-247 (2000).
7. Mitic LL, Van Itallie CM, Anderson JM. Molecular physiology and pathophysiology of tight junctions I. Tight junction structure and function: lessons from mutant animals and proteins. Am. J. Physiol. Gastrointest. Liver Physiol. 279(2), G250-G254 (2000).
8. Krause G, Winkler L, Mueller SL, Haseloff RF, Piontek J, Blasig IE. Structure and function of claudins. Biochim. Biophys. Acta 1778(3), 631-645 (2008).
9. Van Itallie CM, Anderson JM. Claudins and epithelial paracellular transport. Ann. Rev. Physiol. 68, 403-429 (2006).
10. Van Itallie CM, Colegio OR, Anderson JM. The cytoplasmic tails of claudins can influence tight junction barrier properties through effects on protein stability. J. Membr. Biol. 199(1), 29-38 (2004).
11. Al-Sadi R, Khatib K, Guo S, Ye D, Youssef M, Ma T. Occludin regulates macromolecule flux across the intestinal epithelial tight junction barrier. Am. J. Physiol. Gastrointest. Liver Physiol. 300(6), G1054-G1064 (2011).
12. Piontek J, Winkler L, Wolburg H et al. Formation of tight junction: determinants of homophilic interaction between classic claudins. FASEB J. 22(1), 146-158 (2008).
13. Hartsock A, Nelson WJ. Adherens and tight junctions: structure, function and connections to the actin cytoskeleton. Biochim. Biophys. Acta 1778(3), 660-669 (2008).
14. Cummins PM. Occludin: one protein, many forms. Mol. Cell. Biol. 32(2), 242-250 (2012).
15. Van Itallie CM, Fanning AS, Bridges A, Anderson JM. ZO-1 stabilizes the tight junction solute barrier through coupling to the perijunctional cytoskeleton. Mol. Biol. Cell. 20(17), 3930-3940 (2009).
16. Van Itallie CM, Holmes J, Bridges A, Anderson JM. Claudin- 2-dependent changes in noncharged solute flux are mediated by the extracellular domains and require attachment to the PDZ-scaffold. Ann. NY Acad. Sci. 1165, 82-87 (2009).
17. Jain S, Suzuki T, Seth A, Samak G, Rao R. Protein kinase Czeta phosphorylates occludin and promotes assembly of epithelial tight junctions. Biochem J. 437(2), 289-299 (2011).
18. Zheng K, Trivedi M, Siahaan TJ. Structure and function of the intercellular junctions: barrier of paracellular drug delivery. Curr. Pharm. Design 12(22), 2813-2824 (2006).
19. Newman PJ. The biology of PECAM-1. J. Clin. Invest. 100(11 Suppl.), S25-S29 (1997).
20. Newman PJ. Switched at birth: a new family for PECAM-1. J. Clin. Invest. 103(1), 5-9 (1999).
21. Nourshargh S, Krombach F, Dejana E. The role of JAM-A and PECAM-1 in modulating leukocyte infiltration in inflamed and ischemic tissues. J. Leukoc. Biol. 80(4), 714-718 (2006).
22. Woodfin A, Reichel CA, Khandoga A et al. JAM-A mediates neutrophil transmigration in a stimulus-specific manner in vivo: evidence for sequential roles for JAM-A and PECAM-1 in neutrophil transmigration. Blood 110(6), 1848-1856 (2007).
23. Anderson JM, Van Itallie CM. Tight junctions and the molecular basis for regulation of paracellular permeability. Am. J. Physiol. 269(4 Pt 1), G467-G475 (1995).
24. Pal D, Audus KL, Siahaan TJ. Modulation of cellular adhesion in bovine brain microvessel endothelial cells by a decapeptide. Brain Res. 747(1), 103-113 (1997).
25. Rubin LL, Hall DE, Porter S et al. A cell culture model of the blood-brain barrier. J. Cell. Biol. 115(6), 1725-1735 (1991).
26. Rubin LL, Barbu K, Bard F et al. Differentiation of brain endothelial cells in cell culture. Ann. NY Acad. Sci. 633, 420-425 (1991).
27. Yang J, Aschner M. Developmental aspects of blood-brain barrier (BBB) and rat brain endothelial (RBE4) cells as in vitro model for studies on chlorpyrifos transport. Neurotoxicology 24(4-5), 741-745 (2003).
28. Yang J, Mutkus LA, Sumner D et al. Transendothelial permeability of chlorpyrifos in RBE4 monolayers is modulated by astrocyte-conditioned medium. Brain Res. Mol. Brain Res. 97(1), 43-50 (2001).
29. Navarro P, Ruco L, Dejana E. Differential localization of VE-and N-cadherins in human endothelial cells: VE-cadherin competes with N-cadherin for junctional localization. J. Cell. Biol. 140(6), 1475-1484 (1998).
30. Delva E, Tucker DK, Kowalczyk AP. The desmosome. Cold Spring Harb. Perspect. Biol. 1(2), a002543 (2009).
31. Syed SE, Trinnaman B, Martin S, Major S, Hutchinson J, Magee AI. Molecular interactions between desmosomal cadherins. Biochem. J. 362(Pt 2), 317-327 (2002).
32. Chitaev NA, Troyanovsky SM. Direct Ca2+-dependent heterophilic interaction between desmosomal cadherins, desmoglein and desmocollin, contributes to cell-cell adhesion. J. Cell. Biol. 138(1), 193-201 (1997).
33. Lussier C, Basora N, Bouatrouss Y, Beaulieu JF. Integrins as mediators of epithelial cell-matrix interactions in the human small intestinal mucosa. Microsc. Res. Tech. 51(2), 169-178 (2000).
34. Osada T, Gu YH, Kanazawa M et al. Interendothelial claudin-5 expression depends on cerebral endothelial cell-matrix adhesion by beta(1)-integrins. J. Cereb. Blood Flow Metab. 31(10), 1972-1985 (2011).
35. Muradashvili N, Tyagi N, Tyagi R, Munjal C, Lominadze D. Fibrinogen alters mouse brain endothelial cell layer integrity affecting vascular endothelial cadherin. Biochem. Biophys. Res. Commun. 413(4), 509-514 (2011).
36. Tsuge M, Yasui K, Ichiyawa T et al. Increase of tumor necrosis factor-alpha in the blood induces early activation of matrix metalloproteinase-9 in the brain. Microbiol. Immunol. 54(7), 417-424 (2010).
37. Takata F, Dohgu S, Matsumoto J et al. Brain pericytes among cells constituting the blood-brain barrier are highly sensitive to tumor necrosis factor-alpha, releasing matrix metalloproteinase-9 and migrating in vitro. J. Neuroinflammation 8, 106 (2011).
38. Aslam M, Ahmad N, Srivastava R, Hemmer B. TNF-alpha induced NFkappaB signaling and p65 (RelA) overexpression repress Cldn5 promoter in mouse brain endothelial cells. Cytokine 57(2), 269-275 (2012).
39. Betz AL, Firth JA, Goldstein GW. Polarity of the blood-brain barrier: distribution of enzymes between the luminal and antiluminal membranes of brain capillary endothelial cells. Brain Res. 192(1), 17-28 (1980).
40. Meyer RP, Gehlhaus M, Knoth R, Volk B. Expression and function of cytochrome p450 in brain drug metabolism. Curr. Drug Metab. 8(4), 297-306 (2007).
41. Brownlees J, Williams CH. Peptidases, peptides, and the mammalian blood-brain barrier. J. Neurochem. 60(3), 793-803 (1993).
42. Frank RT, Aboody KS, Najbauer J. Strategies for enhancing antibody delivery to the brain. Biochim. Biophys. Acta 1816(2), 191-198 (2011).
43. Mandery K, Glaeser H, Fromm MF. Interaction of innovative small molecule drugs used for cancer therapy with drug transporters. Br. J. Pharmacol. 165(2), 345-362 (2012).
44. Demeule M, Regina A, Jodoin J et al. Drug transport to the brain: key roles for the efflux pump P-glycoprotein in the blood-brain barrier. Vascul. Pharmacol. 38(6), 339-348 (2002).
45. Fojo A, Cornwell M, Cardarelli C et al. Molecular biology of drug resistance. Breast Cancer Res. Treat. 9(1), 5-16 (1987).
46. Ueda K, Cardarelli C, Gottesman MM, Pastan I. Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine. Proc. Natl Acad. Sci. USA 84(9), 3004-3008 (1987).
47. Vogelgesang S, Jedlitschky G, Brenn A, Walker LC. The role of the ATP-binding cassette transporter P-glycoprotein in the transport of beta-amyloid across the blood-brain barrier. Curr. Pharm. Des. 17(26), 2778-2786 (2011).
48. Ouyang H, Andersen TE, Chen W, Nofsinger R, Steffansen B, Borchardt RT. A comparison of the effects of p-glycoprotein inhibitors on the blood-brain barrier permeation of cyclic prodrugs of an opioid peptide (DADLE). J. Pharm. Sci. 98(6), 2227-2236 (2009).
49. Namanja HA, Emmert D, Davis DA et al. Toward eradicating HIV reservoirs in the brain: inhibiting P-glycoprotein at the blood-brain barrier with prodrug abacavir dimers. J. Am. Chem. Soc. 134(6), 2976-2980 (2012).
50. MacLean C, Moenning U, Reichel A, Fricker G. Closing the gaps: a full scan of the intestinal expression of p-glycoprotein, breast cancer resistance protein, and multidrug resistance- associated protein 2 in male and female rats. Drug Metab. Dispos. 36(7), 1249-1254 (2008).
51. Laska DA, Houchins JO, Pratt SE et al. Characterization and application of a vinblastine-selected CACO-2 cell line for evaluation of p-glycoprotein. In Vitro Cell Dev. Biol. Anim. 38(7), 401-410 (2002).
52. Ouyang H, Chen W, Andersen TE, Steffansen B, Borchardt RT. Factors that restrict the intestinal cell permeation of cyclic prodrugs of an opioid peptide (DADLE): Part I. Role of efflux transporters in the intestinal mucosa. J. Pharm. Sci. 98(1), 337-348 (2009).
53. Ekins S, Kim RB, Leake BF et al. Application of three-dimensional quantitative structure-activity relationships of P-glycoprotein inhibitors and substrates. Mol. Pharmacol. 61(5), 974-981 (2002).
54. Ekins S, Kim RB, Leake BF et al. Three-dimensional quantitative structure-activity relationships of inhibitors of P-glycoprotein. Mol. Pharmacol. 61(5), 964-973 (2002).
55. Dantzig AH, Shepard RL, Law KL et al. Selectivity of the multidrug resistance modulator, LY335979, for P-glycoprotein and effect on cytochrome P-450 activities. J. Pharmacol. Exp. Ther. 290(2), 854-862 (1999).
56. Malavolta L, Cabral FR. Peptides: important tools for the treatment of central nervous system disorders. Neuropeptides 45(5), 309-316 (2011).
57. Liu Y, Huang R, Han L et al. Brain-targeting gene delivery and cellular internalization mechanisms for modified rabies virus glycoprotein RVG29 nanoparticles. Biomaterials 30(25), 4195-4202 (2009).
58. Pardridge WM. Blood-brain barrier delivery of protein and non-viral gene therapeutics with molecular Trojan horses. J. Control Release 122(3), 345-348 (2007).
59. Fu A, Wang Y, Zhan L, Zhou R. Targeted delivery of proteins into the central nervous system mediated by rabies virus glycoprotein-derived peptide. Pharm. Res. 29(6), 1562-1569 (2012).
60. Sarkar G, Curran GL, Mahlum E et al. A carrier for non-covalent delivery of functional beta-galactosidase and antibodies against amyloid plaques and IgM to the brain. PLoS ONE 6(12), e28881 (2011).
61. Gabathuler R. Approaches to transport therapeutic drugs across the blood-brain barrier to treat brain diseases. Neurobiol. Dis. 37(1), 48-57 (2010).
62. Banks WA, Gertler A, Solomon G et al. Principles of strategic drug delivery to the brain (SDDB): development of anorectic and orexigenic analogs of leptin. Physiol. Behav. 105(1), 145-149 (2011).
63. Deli MA. Potential use of tight junction modulators to reversibly open membranous barriers and improve drug delivery. Biochim. Biophys. Acta 1788(4), 892-910 (2009).
64. Pardridge WM, Mietus LJ. Transport of steroid hormones through the rat blood-brain barrier. Primary role of albumin-bound hormone. J. Clin. Invest. 64(1), 145-154 (1979).
65. Conradi RA, Burton PS, Borchardt RT. Physico-chemical and biological factors that influence a drug's cellular permeability by passive diffusion. In: Lipophilicity in Drug Action and Toxicology. Pliska, V, Testa, B, Waterbeemd, HV (Eds). Wiley-VCH, Weinheim, Germany, 233-250 (1996).
66. Bundgaard H, Nielsen NM. Esters of N, N-disubstituted 2-hydroxyacetamides as a novel highly biolabile prodrug type for carboxylic acid agents. J. Med. Chem. 30(3), 451-454 (1987).
67. Stella VJ, Nti-Addae KW. Prodrug strategies to overcome poor water solubility. Adv. Drug Deliv. Rev. 59(7), 677-694 (2007).
68. Krise JP, Narisawa S, Stella VJ. A novel prodrug approach for tertiary amines. 2. Physicochemical and in vitro enzymatic evaluation of selected N-phosphonooxymethyl prodrugs. J. Pharm. Sci. 88(9), 922-927 (1999).
69. Singer SJ, Nicolson GL. The fluid mosaic model of the structure of cell membranes. Science 175(4023), 720-731 (1972).
70. Lipinski C, Hopkins A. Navigating chemical space for biology and medicine. Nature 432(7019), 855-861 (2004).
71. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 46(1-3), 3-26 (2001).
72. Oldendorf WH, Hyman S, Braun L, Oldendorf SZ. Blood-brain barrier: penetration of morphine, codeine, heroin, and methadone after carotid injection. Science 178(4064), 984-986 (1972).
73. Lecomte JM, Costentin J, Vlaiculescu A et al. Pharmacological properties of acetorphan, a parenterally active" enkephalinase" inhibitor. J. Pharmacol. Exp. Ther. 237(3), 937-944 (1986).
74. Nassereddine-Sebaei M, Crider AM, Carroll RT, Hinko CN. Determination of m-nitrophenol and nipecotic acid in mouse tissues by high-performance liquid chromatography after administration of the anticonvulsant m-nitrophenyl-3-piperidinecarboxylate hydrochloride. J. Pharm. Sci. 82(1), 39-43 (1993).
75. Gudmundsson OS, Jois SD, Vander Velde DG, Siahaan TJ, Wang B, Borchardt RT. The effect of conformation on the membrane permeation of coumarinic acid- and phenylpropionic acid-based cyclic prodrugs of opioid peptides. J. Pept. Res. 53(4), 383-392 (1999).
76. Gudmundsson OS, Pauletti GM, Wang W et al. Coumarinic acid-based cyclic prodrugs of opioid peptides that exhibit metabolic stability to peptidases and excellent cellular permeability. Pharm. Res. 16(1), 7-15 (1999).
77. Wang B, Nimkar K, Wang W et al. Synthesis and evaluation of the physicochemical properties of esterase-sensitive cyclic prodrugs of opioid peptides using coumarinic acid and phenylpropionic acid linkers. J. Pept. Res. 53(4), 370-382 (1999).
78. Wang B, Shan D, Wang W, Zhang H, Gudmundsson O, Borchardt RT. Synthesis of coumarin-based, esterase-sensitive cyclic prodrugs of opioid peptides with enhanced membrane permeability and enzymatic stability. Methods Mol. Med. 23, 71-85 (1999).
79. Bak A, Gudmundsson OS, Friis GJ, Siahaan TJ, Borchardt RT. Acyloxyalkoxy-based cyclic prodrugs of opioid peptides: evaluation of the chemical and enzymatic stability as well as their transport properties across Caco-2 cell monolayers. Pharm. Res. 16(1), 24-29 (1999).
80. Bak A, Siahaan TJ, Gudmundsson OS, Gangwar S, Friis GJ, Borchardt RT. Synthesis and evaluation of the physicochemical properties of esterase-sensitive cyclic prodrugs of opioid peptides using an (acyloxy)alkoxy linker. J. Pept. Res. 53(4), 393-402 (1999).
81. Gudmundsson OS, Nimkar K, Gangwar S, Siahaan T, Borchardt RT. Phenylpropionic acid-based cyclic prodrugs of opioid peptides that exhibit metabolic stability to peptidases and excellent cellular permeation. Pharm. Res. 16(1), 16-23 (1999).
82. Gudmundsson OS, Vander Velde DG, Jois SD, Bak A, Siahaan TJ, Borchardt RT. The effect of conformation of the acyloxyalkoxy-based cyclic prodrugs of opioid peptides on their membrane permeability. J. Pept. Res. 53(4), 403-413 (1999).
83. Liederer BM, Fuchs T, Vander Velde D, Siahaan TJ, Borchardt RT. Effects of amino acid chirality and the chemical linker on the cell permeation characteristics of cyclic prodrugs of opioid peptides. J. Med. Chem. 49(4), 1261-1270 (2006).
84. Ouyang H, Tang F, Siahaan TJ, Borchardt RT. A modified coumarinic acid-based cyclic prodrug of an opioid peptide: its enzymatic and chemical stability and cell permeation characteristics. Pharm. Res. 19(6), 794-801 (2002).
85. Ouyang H, Vander Velde DG, Borchardt RT, Siahaan TJ. Synthesis and conformational analysis of a coumarinic acid-based cyclic prodrug of an opioid peptide with modified sensitivity to esterase-catalyzed bioconversion. J. Pept. Res. 59(4), 183-195 (2002).
86. He HT, Xu CR, Song X, Siahaan TJ. Syntheses of cyclic prodrugs of RGD peptidomimetics with various macrocyclic ring sizes: evaluation of physicochemical, transport and antithrombic properties. J. Pept. Res. 61(6), 331-342 (2003).
87. Song X, Xu CR, He HT, Siahaan TJ. Synthesis of a novel cyclic prodrug of RGD peptidomimetic to improve its cell membrane permeation. Bioorg. Chem. 30(4), 285-301 (2002).
88. Wang B, Wang W, Camenisch GP, Elmo J, Zhang H, Borchardt RT. Synthesis and evaluation of novel coumarin-based esterase-sensitive cyclic prodrugs of peptidomimetic RGD analogs with improved membrane permeability. Chem. Pharm. Bull. 47(1), 90-95 (1999).
89. Wang W, Borchardt RT, Wang B. Orally active peptidomimetic RGD analogs that are glycoprotein IIb/IIIa antagonists. Curr. Med. Chem. 7(4), 437-453 (2000).
90. Wang W, Camenisch G, Sane DC et al. A coumarin-based prodrug strategy to improve the oral absorption of RGD peptidomimetics. J. Control Release 65(1-2), 245-251 (2000).
91. Gangwar S, Jois SD, Siahaan TJ, Vander Velde DG, Stella VJ, Borchardt RT. The effect of conformation on membrane permeability of an acyloxyalkoxy-linked cyclic prodrug of a model hexapeptide. Pharm. Res. 13(11), 1657-1662 (1996).
92. Gangwar S, Pauletti GM, Siahaan TJ, Stella VJ, Borchardt RT. Synthesis of an esterase-sensitive cyclic prodrug of a model hexapeptide having enhanced membrane permeability and enzymatic stability using an acyloxyalkoxy promoiety. Methods Mol. Med. 23, 37-51 (1999).
93. Pauletti GM, Gangwar S, Wang B, Borchardt RT. Esterase-sensitive cyclic prodrugs of peptides: evaluation of a phenylpropionic acid promoiety in a model hexapeptide. Pharm. Res. 14(1), 11-17 (1997).
94. Wang B, Gangwar S, Pauletti G, Siahaan T, Borchardt RT. Synthesis of an esterase-sensitive cyclic prodrug of a model hexapeptide having enhanced membrane permeability and enzymatic stability using a 3-(2'-hydroxy-4',6'- dimethylphenyl)-3,3-dimethyl propionic Acid promoiety. Methods Mol. Med. 23, 53-69 (1999).
95. Ouyang H, Chen W, Andersen TE, Steffansen B, Borchardt RT. Factors that restrict intestinal cell permeation of cyclic prodrugs of an opioid peptide (DADLE): Part II. Role of metabolic enzymes in the intestinal mucosa. J. Pharm. Sci. 98(1), 349-361 (2009).
96. Liederer BM, Phan KT, Ouyang H, Borchardt RT. Significant differences in the disposition of cyclic prodrugs of opioid peptides in rats and guinea pigs following IV administration. J. Pharm. Sci. 94(12), 2676-2687 (2005).
97. Nofsinger R, Borchardt RT. Factors that restrict the cell permeation of cyclic prodrugs of an opioid peptide, part 4: Characterization of the biopharmaceutical and physicochemical properties of two new cyclic prodrugs designed to be stable to oxidative metabolism by cytochrome P-450 enzymes in the intestinal mucosa. J. Pharm. Sci. 101(9), 3500-3510 (2012).
98. Nofsinger R, Fuchs-Knotts T, Borchardt RT. Factors that restrict the cell permeation of cyclic prodrugs of an opioid peptide, part 3: Synthesis of analogs designed to have improved stability to oxidative metabolism. J. Pharm. Sci. 101(9), 3486-3499 (2012).
99. Osherovich L. Beating the brain's bouncer. SciBX 2, 2(19), (2009) www.nature.com/scibx/journal/v2/n19/fig-tab/scibx.2773-F2001.html
100. Chikhale EG, Burton PS, Borchardt RT. The effect of verapamil on the transport of peptides across the blood-brain barrier in rats: kinetic evidence for an apically polarized efflux mechanism. J. Pharmacol. Exp. Ther. 273(1), 298-303 (1995)
101. Dantzig AH, Shepard RL, Cao J et al. Reversal of P-glycoprotein-mediated multidrug resistance by a potent cyclopropyldibenzosuberane modulator, LY335979. Cancer Res. 56(18), 4171-4179 (1996).
102. Boesch D, Muller K, Pourtier-Manzanedo A, Loor F. Restoration of daunomycin retention in multidrug-resistant P388 cells by submicromolar concentrations of SDZ PSC 833, a nonimmunosuppressive cyclosporin derivative. Exp. Cell Res. 196(1), 26-32 (1991).
103. Dantzig AH, de Alwis DP, Burgess M. Considerations in the design and development of transport inhibitors as adjuncts to drug therapy. Adv. Drug Deliv. Rev. 55(1), 133-150 (2003).
104. Boote DJ, Dennis IF, Twentyman PR et al. Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer. J. Clin. Oncol. 14(2), 610-618 (1996).
105. Werle M. Natural and synthetic polymers as inhibitors of drug efflux pumps. Pharm. Res. 25(3), 500-511 (2008).
106. Nerurkar MM, Burton PS, Borchardt RT. The use of surfactants to enhance the permeability of peptides through Caco-2 cells by inhibition of an apically polarized efflux system. Pharm. Res. 13(4), 528-534 (1996).
107. Nerurkar MM, Ho NF, Burton PS, Vidmar TJ, Borchardt RT. Mechanistic roles of neutral surfactants on concurrent polarized and passive membrane transport of a model peptide in Caco-2 cells. J. Pharm. Sci. 86(7), 813-821 (1997).
108. Namanja HA, Emmert D, Pires MM, Hrycyna CA, Chmielewski J. Inhibition of human P-glycoprotein transport and substrate binding using a galantamine dimer. Biochem. Biophys. Research Commun. 388(4), 672-676 (2009).
109. Kaufmann AM, Krise JP. Lysosomal sequestration of amine-containing drugs: analysis and therapeutic implications. J. Pharm. Sci. 96(4), 729-746 (2007).
110. Trapp S, Rosania GR, Horobin RW, Kornhuber J. Quantitative modeling of selective lysosomal targeting for drug design. Eur. Biophys. J. 37(8), 1317-1328 (2008).
111. Heikkinen AT, Monkkonen J, Korjamo T. Kinetics of cellular retention during Caco-2 permeation experiments: role of lysosomal sequestration and impact on permeability estimates. J. Pharmacol. Exp. Ther. 328(3), 882-892 (2009).
112. Hayeshi R, Masimirembwa C, Mukanganyama S, Ungell AL. Lysosomal trapping of amodiaquine: impact on transport across intestinal epithelia models. Biopharm. Drug Disp. 29(6), 324-334 (2008).
113. Chabner BA, Allegra CJ, Curt GA et al. Polyglutamation of methotrexate. Is methotrexate a prodrug? J. Clin. Invest. 76(3), 907-912 (1985).
114. Chen G, Fawcett JP, Mikov M, Tucker IG. Simultaneous determination of methotrexate and its polyglutamate metabolites in Caco-2 cells by liquid chromatography-tandem mass spectrometry. J. Pharm. Biomed. Anal. 50(2), 262-266 (2009).
115. Chen G, Fawcett JP, Mikov M, Tucker IG. Monoketocholate can decrease transcellular permeation of methotrexate across Caco-2 cell monolayers and reduce its intestinal absorption in rat. J. Pharm. Pharmacol. 61(7), 953-959 (2009).
116. Funk RS, Krise JP. Cationic amphiphilic drugs cause a marked expansion of apparent lysosomal volume: implications for an intracellular distribution-based drug interaction. Mol. Pharm. 9(5), 1384-1395 (2012).
117. Logan R, Funk RS, Axcell E, Krise JP. Drug-drug interactions involving lysosomes: mechanisms and potential clinical implications. Expert Opin. Drug Metab. Toxicol. 8(8), 943-958 (2012).
118. Ndolo RA, Luan Y, Duan S, Forrest ML, Krise JP. Lysosomotropic properties of weakly basic anticancer agents promote cancer cell selectivity in vitro. PLoS ONE 7(11), e49366 (2012).
119. Morita K, Sasaki H, Furuse M, Tsukita S. Endothelial claudin: claudin-5/TMVCF constitutes tight junction strands in endothelial cells. J. Cell. Biol. 147(1), 185-194 (1999).
120. Ganapathy, Leibach FH. Is intestinal peptide transport energized by a proton gradient? Am. J. Physiol. 249(2 Pt 1), G153-G160 (1985).
121. Hidalgo IJ, Bhatnagar P, Lee CP, Miller J, Cucullino G, Smith PL. Structural requirements for interaction with the oligopeptide transporter in Caco-2 cells. Pharm. Res. 12(2), 317-319 (1995).
122. Thwaites DT, Cavet M, Hirst BH, Simmons NL. Angiotensin-converting enzyme (ACE) inhibitor transport in human intestinal epithelial (Caco-2) cells. Br. J. Pharmacol. 114, 981-986 (1995).
123. Bueno AB, Collado I, de Dios A et al. Dipeptides as effective prodrugs of the unnatural amino acid (+)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY354740), a selective group II metabotropic glutamate receptor agonist. J. Med. Chem. 48(16), 5305-5320 (2005).
124. Dantzig AH, Bergin L. Uptake of the cephalosporin, cephalexin, by a dipeptide transport carrier in the human intestinal cell line, Caco-2. Biochim. Biophys. Acta 1027(3), 211-217 (1990).
125. Dantzig AH, Tabas LB, Bergin L. Cefaclor uptake by the proton-dependent dipeptide transport carrier of human intestinal Caco-2 cells and comparison to cephalexin uptake. Biochim. Biophys. Acta 1112(2), 167-173 (1992).
126. Snyder NJ, Tabas LB, Berry DM, Duckworth DC, Spry DO, Dantzig AH. Structure-activity relationship of carbacephalosporins and cephalosporins: antibacterial activity and interaction with the intestinal proton-dependent dipeptide transport carrier of Caco-2 cells. Antimicrob. Agents Chemother. 41(8), 1649-1657 (1997).
127. Abbott NJ, Ronnback L, Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat. Rev. Neurosci. 7(1), 41-53 (2006).
128. Gupta SV, Gupta D, Sun J et al. Enhancing the intestinal membrane permeability of zanamivir: a carrier mediated prodrug approach. Mol. Pharm. 8(6), 2358-2367 (2011).
129. Landowski CP, Sun D, Foster DR et al. Gene expression in the human intestine and correlation with oral valacyclovir pharmacokinetic parameters. J. Pharmacol. Exp. Ther. 306(2), 778-786 (2003).
130. Landowski CP, Han HK, Lee KD, Amidon GL. A fluorescent hPept1 transporter substrate for uptake screening. Pharm. Res. 20(11), 1738-1745 (2003).
131. Pardridge WM. Drug targeting to the brain. Pharm. Res. 24(9), 1733-1744 (2007).
132. Pardridge WM, Boado RJ. Reengineering biopharmaceuticals for targeted delivery across the blood-brain barrier. Methods Enzymol. 503, 269-292 (2012).
133. Staquicini FI, Ozawa MG, Moya CA et al. Systemic combinatorial peptide selection yields a non-canonical iron-mimicry mechanism for targeting tumors in a mouse model of human glioblastoma. J. Clin. Invest. 121(1), 161-173 (2011).
134. Neuwelt E, Abbott NJ, Abrey L et al. Strategies to advance translational research into brain barriers. Lancet Neurol. 7(1), 84-96 (2008).
135. Neuwelt EA, Barnett PA, Bigner DD, Frenkel EP. Effects of adrenal cortical steroids and osmotic blood-brain barrier opening on methotrexate delivery to gliomas in the rodent: the factor of the blood-brain barrier. Proc. Natl Acad. Sci. USA 79(14), 4420-4423 (1982).
136. Neuwelt EA, Hill SA, Frenkel EP. Osmotic blood-brain barrier modification and combination chemotherapy: concurrent tumor regression in areas of barrier opening and progression in brain regions distant to barrier opening. Neurosurgery 15(3), 362-366 (1984).
137. Neuwelt EA, Maravilla KR, Frenkel EP, Rapaport SI, Hill SA, Barnett PA. Osmotic blood-brain barrier disruption. Computerized tomographic monitoring of chemotherapeutic agent delivery. J. Clin. Invest. 64(2), 684-688 (1979).
138. Neuwelt EA, Specht HD, Barnett PA et al. Increased delivery of tumor-specific monoclonal antibodies to brain after osmotic blood-brain barrier modification in patients with melanoma metastatic to the central nervous system. Neurosurgery 20(6), 885-895 (1987).
139. Rao R. Occludin phosphorylation in regulation of epithelial tight junctions. Ann. NY Acad. Sci. 1165, 62-68 (2009).
140. Van Itallie CM, Tietgens AJ, LoGrande K, Aponte A, Gucek M, Anderson JM. Phosphorylation of claudin-2 on serine 208 promotes membrane retention and reduces trafficking to lysosomes. J. Cell Sci. 125(Pt 20), 4902-4912 (2012).
141. Suzuki T, Elias BC, Seth A et al. PKC eta regulates occludin phosphorylation and epithelial tight junction integrity. Proc. Natl Acad. Sci. USA 106(1), 61-66 (2009).
142. Zwanziger D, Staat C, Andjelkovic AV, Blasig IE. Claudin-derived peptides are internalized via specific endocytosis pathways. Ann. NY Acad. Sci. 1257, 29-37 (2012).
143. Zwanziger D, Hackel D, Staat C et al. A peptidomimetic tight junction modulator to improve regional analgesia. Mol. Pharm. 9(6), 1785-1794 (2012).
144. Baumgartner HK, Beeman N, Hodges RS, Neville MC. A D-peptide analog of the second extracellular loop of claudin-3 and -4 leads to mislocalized claudin and cellular apoptosis in mammary epithelial cells. Chem. Biol. Drug Des. 77(2), 124-136 (2011).
145. Wong V, Gumbiner BM. A synthetic peptide corresponding to the extracellular domain of occludin perturbs the tight junction permeability barrier. J. Cell. Biol. 136(2), 399-409 (1997).
146. Chung NP, Mruk D, Mo MY, Lee WM, Cheng CY. A 22-amino acid synthetic peptide corresponding to the second extracellular loop of rat occludin perturbs the blood-testis barrier and disrupts spermatogenesis reversibly in vivo. Biol. Reprod. 65(5), 1340-1351 (2001).
147. Wong CH, Mruk DD, Lee WM, Cheng CY. Targeted and reversible disruption of the blood-testis barrier by an FSH mutant-occludin peptide conjugate. FASEB J. 21(2), 438-448 (2007).
148. Tavelin S, Hashimoto K, Malkinson J, Lazorova L, Toth I, Artursson P. A new principle for tight junction modulation based on occludin peptides. Mol. Pharmacol. 64(6), 1530-1540 (2003).
149. Salama NN, Fasano A, Thakar M, Eddington ND. The impact of DeltaG on the oral bioavailability of low bioavailable therapeutic agents. J. Pharmacol. Exp. Ther. 312(1), 199-205 (2005).
150. Salama NN, Eddington ND, Fasano A. Tight junction modulation and its relationship to drug delivery. Adv. Drug Deliv. Rev. 58(1), 15-28 (2006).
151. Lu R, Wang W, Uzzau S, Vigorito R, Zielke HR, Fasano A. Affinity purification and partial characterization of the zonulin/zonula occludens toxin (Zot) receptor from human brain. J. Neurochem. 74(1), 320-326 (2000).
152. Salama NN, Fasano A, Lu R, Eddington ND. Effect of the biologically active fragment of zonula occludens toxin, delta G, on the intestinal paracellular transport and oral absorption of mannitol. Int. J. Pharm. 251(1-2), 113-121 (2003).
153. Salama NN, Fasano A, Thakar M, Eddington ND. The effect of delta G on the transport and oral absorption of macromolecules. J. Pharm. Sci. 93(5), 1310-1319 (2004).
154. Motlekar NA, Fasano A, Wachtel MS, Youan BB. Zonula occludens toxin synthetic peptide derivative AT1002 enhances in vitro and in vivo intestinal absorption of low molecular weight heparin. J. Drug Target. 14(5), 321-329 (2006).
155. Gopalakrishnan S, Pandey N, Tamiz AP et al. Mechanism of action of ZOT-derived peptide AT-1002, a tight junction regulator and absorption enhancer. Int. J. Pharm. 365(1-2), 121-130 (2009).
156. Makagiansar IT, Avery M, Hu Y, Audus KL, Siahaan TJ. Improving the selectivity of HAV-peptides in modulating E-cadherin-E-cadherin interactions in the intercellular junction of MDCK cell monolayers. Pharm. Res. 18(4), 446-453 (2001).
157. Calcagno AM, Fostel JM, Reyner EL et al. Effects of an E-cadherin-derived peptide on the gene expression of Caco-2 cells. Pharm. Res. 21, 2095-2104 (2004).
158. Sinaga E, Jois SD, Avery M et al. Increasing paracellular porosity by E-cadherin peptides: Discovery of bulge and groove regions in the EC1-domain of E-cadherin. Pharm. Res. 19, 1170-1179 (2002).
159. Kobayashi N, Ikesue A, Majumdar S, Siahaan TJ. Inhibition of E-cadherin-mediated homotypic adhesion of Caco-2 cells: a novel evaluation assay for peptide activities in modulating cell-cell adhesion. J. Pharmacol. Exp. Ther. 317, 309-316 (2006).
160. Kiptoo P, Sinaga E, Calcagno AM et al. Enhancement of drug absorption through the blood-brain barrier and inhibition of intercellular tight junction resealing by E-cadherin peptides. Mol. Pharm. 8(1), 239-249 (2011).
161. On NH, Kiptoo P, Siahaan TJ, Miller DW. Modulation of blood-brain barrier permeability in mice using synthetic E-cadherin peptide. Mol. Pharm. 11(3), 974-981 (2014).
162. Zheng K, Laurence JS, Kuczera K, Verkhivker G, Middaugh CR, Siahaan TJ. Characterization of multiple stable conformers of the EC5 domain of E-cadherin and the interaction of EC5 with E-cadherin peptides. Chem. Biol. Drug Des. 73(6), 584-598 (2009).
163. Yun Y, Cho YW, Park K. Nanoparticles for oral delivery: targeted nanoparticles with peptidic ligands for oral protein delivery. Adv. Drug Deliv. Rev. 65(6), 822-832 (2013).
164. Chen Y, Liu L. Modern methods for delivery of drugs across the blood-brain barrier. Adv. Drug Deliv. Rev. 64(7), 640-665 (2012).
165. Wohlfart S, Gelperina S, Kreuter J. Transport of drugs across the blood-brain barrier by nanoparticles. J. Control Release 161(2), 264-273 (2012).
166. Michaelis K, Hoffmann MM, Dreis S et al. Covalent linkage of apolipoprotein e to albumin nanoparticles strongly enhances drug transport into the brain. J. Pharmacol. Exp. Ther. 317(3), 1246-1253 (2006).
167. Ulbrich K, Hekmatara T, Herbert E, Kreuter J. Transferrin- and transferrin-receptor-antibody-modified nanoparticles enable drug delivery across the blood-brain barrier (BBB). Eur. J. Pharm. Biopharm. 71(2), 251-256 (2009).
168. Salvati E, Re F, Sesana S et al. Liposomes functionalized to overcome the blood-brain barrier and to target amyloid-beta peptide: the chemical design affects the permeability across an in vitro model. Int. J. Nanomed. 8, 1749-1758 (2013).
169. Ulbrich K, Knobloch T, Kreuter J. Targeting the insulin receptor: nanoparticles for drug delivery across the blood-brain barrier (BBB). J. Drug Target. 19(2), 125-132 (2011).
170. Hillaireau H, Couvreur P. Nanocarriers' entry into the cell: relevance to drug delivery. Cell. Mol. Life Sci. 66(17), 2873-2896 (2009).
171. Garcia-Garcia E, Andrieux K, Gil S, Couvreur P. Colloidal carriers and blood-brain barrier (BBB) translocation: a way to deliver drugs to the brain? Int. J. Pharm. 298(2), 274-292 (2005).
172. Chen H, Qin Y, Zhang Q et al. Lactoferrin modified doxorubicin-loaded procationic liposomes for the treatment of gliomas. Eur. J. Pharm. Sci. 44(1-2), 164-173 (2011).
173. Beier CP, Schmid C, Gorlia T et al. RNOP-09: pegylated liposomal doxorubicine and prolonged temozolomide in addition to radiotherapy in newly diagnosed glioblastoma - a Phase II study. BMC Cancer 9, 308 (2009).